Tilray Brands (NASDAQ:TLRY) Trading Up 5.3% – Should You Buy?

Tilray Brands, Inc. (NASDAQ:TLRY) shares traded up 5.3% on Thursday . The company traded as high as $4.25 and last traded at $4.20. 7,787,848 shares traded hands during mid-day trading, an increase of 81% from the average daily volume of 4,300,223 shares. The stock had previously closed at $3.99.

Key Headlines Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Jefferies maintained its “Buy” rating and said Tilray is making progress toward becoming a diversified consumer-products company spanning cannabis, beverages, hospitality and wellness. The firm cited potential long-term value creation despite reducing its price target to $19 from a higher prior target. Tilray Brands seen creating long-term value through diversified platform, Jefferies says
• Positive Sentiment: Fiscal 2026 revenue reached a record $915 million, while gross profit and adjusted EBITDA also set records. International medical cannabis revenue rose 34% for the year, and the BrewDog acquisition expanded Tilray’s beverage platform and geographic reach. Tilray Brands delivers record fiscal 2026 revenue and adjusted EBITDA
• Neutral Sentiment: Fourth-quarter revenue rose 25.5% year over year to approximately $281.7 million, exceeding analyst expectations, and gross profit increased 33.8% to $90.5 million. However, the quarter’s results reflected the ongoing trade-off between rapid expansion and near-term earnings performance. Tilray Brands releases Q4 2026 earnings
• Negative Sentiment: Tilray reported a fourth-quarter loss of $0.43 per share, substantially worse than the expected loss of roughly $0.01-$0.02. Net loss attributable to common shareholders was $49.6 million, operating cash flow was negative $37.3 million, and adjusted net income declined sharply year over year. Tilray Brands reports Q4 loss, beats revenue estimates
• Negative Sentiment: Management’s fiscal 2027 adjusted EBITDA outlook of $68 million to $75 million is below the approximately $84 million consensus estimate. Jefferies consequently lowered its fiscal 2027 and 2028 forecasts, while analysts continue to flag share dilution and stagnant segment margins as obstacles to profitability. Tilray projects fiscal 2027 adjusted EBITDA
• Negative Sentiment: The broader trend remains weak: TLRY has fallen substantially this year and is trading near multiyear lows. Persistent losses, negative cash generation and dilution continue to outweigh the company’s revenue growth for more cautious investors. Tilray Q4: Dilution outweighs progress

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on TLRY shares. Weiss Ratings lowered shares of Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. TD Cowen dropped their price objective on shares of Tilray Brands from $7.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, July 14th. ATB Cormark Capital Markets reduced their target price on Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating on the stock in a research note on Thursday, April 2nd. Finally, Roth Capital raised Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a research note on Thursday, April 2nd. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $11.00.

Tilray Brands Stock Performance

The stock has a market cap of $489.51 million, a PE ratio of -3.89 and a beta of 1.89. The company has a fifty day moving average price of $4.71 and a 200 day moving average price of $6.31. The company has a quick ratio of 1.66, a current ratio of 2.79 and a debt-to-equity ratio of 0.19.

Tilray Brands (NASDAQ:TLRY) last released its earnings results on Tuesday, July 28th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.42). The company had revenue of $281.71 million during the quarter, compared to the consensus estimate of $246.30 million. Tilray Brands had a negative net margin of 13.11% and a negative return on equity of 7.84%. Analysts expect that Tilray Brands, Inc. will post -0.34 earnings per share for the current year.

Institutional Trading of Tilray Brands

Institutional investors have recently made changes to their positions in the stock. Hilton Head Capital Partners LLC purchased a new position in shares of Tilray Brands in the fourth quarter worth $38,000. Cerity Partners LLC boosted its position in Tilray Brands by 98.5% during the 2nd quarter. Cerity Partners LLC now owns 92,560 shares of the company’s stock valued at $38,000 after buying an additional 45,929 shares during the period. Marex Group plc purchased a new stake in Tilray Brands during the 2nd quarter valued at $40,000. Hilton Capital Management LLC bought a new stake in Tilray Brands in the 2nd quarter worth $41,000. Finally, Essential Partners LLC grew its holdings in Tilray Brands by 110,137.5% in the 1st quarter. Essential Partners LLC now owns 8,819 shares of the company’s stock worth $57,000 after acquiring an additional 8,811 shares during the last quarter. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.